The invention relates to a swimming prosthesis (1) comprising: a connection element (3) which is designed to be coupled to an amputation stump of an amputee; a swimming element (6) which is concave in design and is secured to the distal end of the connection element (3) such that it can pivot with the proximal end.
A63B 31/12 - Swim fins, flippers or other swimming aids held by, or attachable to, the hands, arms, feet or legs held by, or attachable to, the arms or legs
A63B 71/00 - Games or sports accessories not covered in groups
A61F 2/50 - Prostheses not implantable in the body
2.
STAPLE IMPLANT FOR INFLUENCING THE GROWTH IN BONE REGIONS BORDERING AN EPIPHYSEAL PLATE
The invention relates to a staple implant for influencing or guiding the growth in bone regions bordering the epiphyseal plate, said staple having a transverse web (5) and anchoring limbs (2, 3) arranged on the ends of the transverse web (5), running parallel to one another and terminating in points. The anchoring limbs (2, 3), once inserted into the bone, form fixation points (7, 8) on one side of said bone on either side of the epiphyseal plate (13). The transverse web (5) has at least one narrowed zone (9) that can be plastically deformed under a flexural load, said zone having any position and form without abrupt transitions and being situated between the fixation points (7, 8).
The present invention relates to aminopeptidase N (APN) inhibitor conjugates of formula I wherein W is a -CO- or an -SO2- group and at least one of R1 or R2 represents (OCH2- CH2)n-X, where n is an integer of 1 to 100 and X represents H or a detectable label or a therapeutic, and the other represents an alkoxy group or OH, and wherein R3, R3`and R3`` is independently selected from an alkoxy group or (OCH2-CH2)n-X, where n is an integer of 1 to 100 and X represents H or a detectable label or a therapeutic, and R4 is selected from the group comprising: wherein R is an alkyl group. Furthermore, the present invention relates to a diagnostic and/or pharmaceutical composition comprising the conjugate of the invention. The present invention also relates to the conjugate or composition of the invention for use in the diagnosis or treatment of APN-associated diseases like for example angiogenesis in cancer, rheumatoid arthritis, leukemia and diabetic nephropathy, as well as to the use of the conjugate or of the composition of the invention in the diagnosis or treatment of angiogenesis in cancer, rheumatoid arthritis, leukemia and diabetic nephropathy. In a further aspect, the present invention relates to kits comprising the conjugate or composition of the invention. The conjugate or pharmaceutical/diagnostic composition of the invention can also be used in in vivo or in vitro imaging studies of aminopeptidase N.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
The present invention relates in general to a compound which is characterized by a formula selected from the following formulas A, B, C, D, E or F; or a pharmaceutically acceptable salt thereof. The present invention further relates to pharmaceutical composition comprising the inhibitor(s) of the invention and to their use in the treatment of (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer. The present invention furthermore relates to the use of at least one inhibitor of the invention for the preparation of a pharmaceutical composition for the treatment of (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer. The present invention also relates to a method for manufacturing a pharmaceutical composition comprising the steps of formulating the inhibitor defined herein in a pharmaceutically acceptable form.
C07C 233/75 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
C07C 309/39 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing halogen atoms bound to the carbon skeleton
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61P 11/00 - Drugs for disorders of the respiratory system
C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
5.
COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING
The present invention relates to a compound which is characterized by the formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof, wherein the ring systems A and B are independently selected from a monosaccharide, aryl (preferably phenyl), a heteroaryl or cycloalkyl (preferably cyclohexan), preferably with all substituents in equatorial configurations; R1 is independently selected from alkyl (preferably C1 to C6), a substituted or unsubstituted phenyl, preferably CH3; R2 is H, alkyl (preferably C1 to C6), a carbohydrate in a glycosidic β-linkage, preferably H; R3, R4, R5, and R6 are independently selected from H, (OH) hydroxy, alkyl preferably C1 to C6, alkoxy (preferably C1 to C6), amino, alkylamino (preferably C1 to C6), halogen, benzylamino, or benzoylamino; X is O, NH, alkylamino (NR), CO, S; and Y is O, NH, alkylamino (NR), CO, S. The present invention also relates to the compound of the invention and, optionally, a pharmaceutically acceptable carrier, for use in the treatment of (for treating) and/or preventing a disease or medical condition which is associated with mutant CFTR.
C07C 233/75 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61P 11/00 - Drugs for disorders of the respiratory system
6.
NEW ACTIVATORS FOR TREATING AND/OR PREVENTING DISEASES OR MEDICAL CONDITIONS WHICH BENEFIT FROM AN INCREASED TRANSPORT OF HYALURONAN ACROSS A LIPID BILAYER
The present invention relates in general to a compound (activator) which is characterized by a formula selected from the following formulas A, B and/or C or a pharmaceutically acceptable salt thereof. The present invention further relates to pharmaceutical composition comprising the activator(s) of the invention and to their use in the treatment of (for treating) and/or preventing diseases or medical conditions which benefit from an increased transport of hyaluronan across a lipid bilayer. The present invention also relates to a method for manufacturing a pharmaceutical composition comprising the steps of formulating the activator defined herein in a pharmaceutically acceptable form.
C07C 233/75 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61P 11/00 - Drugs for disorders of the respiratory system
7.
MEANS AND METHODS FOR EVALUATING A THERAPY WITH A P38 MAP KINASE INHIBITOR
The present invention relates to a method for determining whether therapy with a p38 MAP kinase inhibitor is potentially beneficial or potentially contraindicated for a subject suffering from a p38-mediated condition comprising measuring in a sample obtained from the subject the presence of at least one chromatin remodelling gene and/or of at least one pro-inflammatory gene, wherein the treatment is potentially beneficial for the subject, if at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition; or wherein the treatment is potentially contraindicated for the subject, if at least one chromatin remodelling gene is overrepresented and/or at least one pro-inflammatory gene is underrepresented in comparison to a reference sample obtained from a subject not suffering from a p38- mediated condition. The present invention also relates to medical uses and methods of treatment applying a p38 MAP kinase inhibitor for treating a p38-mediated condition in a subject, wherein the patient is amenable to the treatment with the p38 MAP kinase inhibitor, if in the subject at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. Furthermore, a packaged medicament and a kit are provided comprising a p38 MAP kinase inhibitor or means for determining the presence of at least one chromatin remodelling gene and/or at least one pro-inflammatory gene in a sample from a subject suffering from a p38-mediated condition and instructions for use indicating that a subject suffering from a p38-mediated condition is amenable to the treatment with the p38 MAP kinase inhibitor, if it has been determined whether in said subject at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition.
Disclosed is a nonpulsatile pump arrangement (1) incorporated into the human blood stream, called an LVAD (left ventricular assist device), for delivering blood while bypassing the left ventricle. Said pump arrangement (1) comprises a duct (2) that conducts the blood and has an inlet at which blood can flow into the duct and an outlet at which blood can flow out of the duct, and also comprises drive means (3) for pumping the blood in the direction of flow. According to the invention, a controller is provided that influences the blood stream discharged from the duct in such a way that in accordance with the coronary activity of the heart contained in the same blood stream as the pump arrangement, blood is fed to the large blood stream essentially during the diastole while no blood is fed essentially during the systole. Furthermore, a sensor arrangement is provided which generates signals correlated to the coronary activity and which is connected to the controller in order to transmit signals.
The present invention relates to the use of Yersinia outer protein M (YopM), a YopM fragment, or a YopM variant, which is capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirement of additional factors for delivering a cargo molecule across the membrane to the cytosol of a cell. The present invention also relates to a pharmaceutical composition comprising YopM, a YopM fragment, or a YopM variant being capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirement of additional factors for the regulation of inflammatory reactions of the immune system and the treatment of diseases caused by autoimmunity of the host. The present invention further relates to a YopM fragment or variant, which is capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirements of additional factors as well as such proteins or YopM linked to a cargo molecule.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
10.
COMPOSITIONS FOR REDUCING OXIDATIVE STRESS AND USES THEREOF
The present invention relates to the use of one or more tripeptides selected from the group consisting of NLys-Pro-ValC, NLys-Pro-ThrCand NpGlu-His-ProC for the reduction of oxidative stress. The above tripeptides are particularly useful for the treatment of a disease or damage caused by oxidative stress; such as vitiligo, scleroderma, necrosis, or erythema; furthermore, a disease or damage of the hair, like premature hair loss or premature formation of grey hair. Furthermore the invention relates the cosmetic use of the above tripeptides, in particular against skin aging. Further the invention relates cosmetic compositions containing at least one of said tripeptides.
The present invention relates to a novel exon of the LHR, namely exon 6A, as well as to mutated forms thereof. Particularly, the present invention relates to a nucleotide sequence of exon 6A, to a nucleotide sequence comprising said nucleotide sequence of exon 6A, to a nucleotide sequence comprising a nucleotide sequence of a splice variant of LHR comprising exon 6A1 to variants or fragments of said nucleotide sequences, as well as to a vector comprising said nucleotide sequences. The present invention further relates to a polypeptide comprising an amino acid sequence encoded by exon 6A or encoded by a splice variant of LHR comprising exon 6A, as well as to variants and fragments of said amino acid sequence. Furthermore, the present invention relates to a host cell genetically engineered with a nucleotide sequence of the present invention or comprising the vector of the present invention. Additionally, the present invention relates to a pharmaceutical composition comprising an inhibitor of exon 6A of LHR. Furthermore, provided herein is a method of diagnosing a disease in a patient which is characterized by an increase of the amount of LHR mRNA comprising exon 6A, to a method for treating, ameliorating or preventing such a disease, as well as to a use of the nucleotide sequence, the vector, the polypeptide or the host cell as provided or the inhibitor of exon 6A as defined in the context of the invention for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of such a disease. The present invention also refers to a method for treating, ameliorating or preventing a disease which is characterized by an increase of the amount of LHR mRNA comprising exon 6A and to a use of the compounds of the invention and an inhibitor of exon 6A for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of such a disease.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to a endothelin receptor antagonist conjugate of the formula (I) wherein R2 is an alkoxy group and one of R1 and R3 represents an alkoxy group and the other represents a group of the formula: (OCH2CH2)n-NH-X, wherein n is an integer of 1 to 100 and X represents a fluorescent dye and tautomers thereof. Furthermore, the present invention relates to a diagnostic composition comprising the compounds of the invention. The present invention also relates to the use of the compounds of the invention for the preparation of a diagnostic composition for the the diagnosis of cancer, the evaluation of cancer biology and/or monitoring of anticancer therapy. In a further aspect, the present invention relates to kits comprising the compounds of the invention.
patents